James Healy - 28 Oct 2026 Form 4 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Reporting relationship: Director
Issuer ticker: RAPP
Reported as of: 28 Oct 2026
Net transaction value: +$20,359,080
SEC form: 4
Accepted by SEC: 30 Oct 2026, 19:32:45 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Nathalie Auber, Attorney-in-Fact

Filing notes and source

Key filing fact

James Healy filed Form 4 for Rapport Therapeutics, Inc. (RAPP) on 30 Oct 2026.

Key facts

This page summarizes James Healy's Form 4 filing for Rapport Therapeutics, Inc. (RAPP).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 30 Oct 2026, 19:32.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: +$20,359,080.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001245624 Primary reporting owner

HEALY JAMES

Relationship: Director
Address: SOFINNOVA INVESTMENTS, INC., 3000 SAND HILL ROAD, BLDG. 3, SUITE 150, MENLO PARK
Signature: /s/ Nathalie Auber, Attorney-in-Fact
Signature date: 30 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RAPP transaction

Common Stock

Purchase

Transaction value: $19,999,980
Shares: +952,380
Change %: +51%
Price: $21.00
Shares after: 2,815,707
Date: 28 Oct 2026
Ownership: By Sofinnova Venture Partners XI, L.P.
Footnotes: F1

RAPP transaction

Common Stock

Purchase

Transaction value: $134,295
Shares: +6,395
Change %: +55%
Price: $21.00
Shares after: 17,990
Date: 28 Oct 2026
Ownership: By SummitTX Master, SPC -SummitTX Apex SP - Healthcare 3
Footnotes: F2

RAPP transaction

Common Stock

Purchase

Transaction value: $79,212
Shares: +3,772
Change %: +34%
Price: $21.00
Shares after: 14,924
Date: 28 Oct 2026
Ownership: By SummitTX Master, SPC - SummitTX Alpha SP - Healthcare 3
Footnotes: F3

RAPP transaction

Common Stock

Purchase

Transaction value: $145,593
Shares: +6,933
Change %: +38%
Price: $21.00
Shares after: 25,267
Date: 28 Oct 2026
Ownership: By SummitTX Pinnacle Master, L.P. - Healthcare 3
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The shares are directly held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. ("SM XI") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F2

The shares are directly held by SummitTX Master, SPC - SummitTX Apex SP - Healthcare 3 (f/k/a Crestline Summit Master, SPC - Crestline Summit Apex SP) ("Apex SP"). Sofinnova BioEquities GP LLC ("BioEquities GP") is the general partner of Apex SP. The Reporting Person is a managing member of BioEquities GP and may be deemed to share voting and dispositive power over the shares held by Apex SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F3

The shares are directly held by SummitTX Master, SPC - SummitTX Alpha SP - Healthcare 3 (f/k/a Crestline Summit Master, SPC - PEAK SP) ("Alpha SP"). BioEquities GP is the general partner of Alpha SP. The Reporting Person is a managing member of BioEquities GP and may be deemed to share voting and dispositive power over the shares held by Alpha SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F4

The shares are directly held by SummitTX Pinnacle Master, L.P. - Healthcare 3 (f/k/a Crestline Summit Pinnacle Master, L.P.) ("Pinnacle LP"). BioEquities GP is the general partner of Pinnacle LP. The Reporting Person is a managing member of BioEquities GP and may be deemed to share voting and dispositive power over the shares held by Pinnacle LP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.